Cited 38 times in
Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강혜민 | - |
dc.contributor.author | 고형준 | - |
dc.date.accessioned | 2014-12-18T08:34:48Z | - |
dc.date.available | 2014-12-18T08:34:48Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0002-9394 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/86571 | - |
dc.description.abstract | PURPOSE: To compare visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) injection or photodynamic therapy (PDT) for idiopathic choroidal neovascularization (CNV). DESIGN: Retrospective study. METHODS: Among 29 eyes (28 patients), 15 eyes (15 patients) received anti-VEGF therapy and 14 eyes (13 patients) received PDT. Best-corrected visual acuity (BCVA, logMAR [logarithm of minimal angle of resolution]) at baseline and 1, 3, 6, 12, and 24 months after initial treatment were compared. The eyes were classified by BCVA changes: improved (improvement ≥0.3 logMAR), decreased (deterioration ≥0.3 logMAR), and stable. RESULTS: Mean BCVA was 0.56 ± 0.38 logMAR (20/72 in Snellen equivalent) in the PDT group and 0.44 ± 0.59 logMAR (20/55 in Snellen equivalent) in the anti-VEGF group at baseline (P = .104, Mann-Whitney U test). The anti-VEGF group showed significantly better mean BCVA at each follow-up visit when compared with that of PDT (P = .004 at 1 month, P = .002 at 3 months, P = .037 at 6 months, P = .031 at 12 months, and P = .049 at 24 months; Mann-Whitney U test, respectively). When compared with the baseline, mean BCVA at each follow-up visit was better in the anti-VEGF group (P = .196 at 1 month, P = .007 at 3 months, P = .046 at 6 months, P = .046 at 12 months, and P = .049 at 24 months; Wilcoxon signed rank test, respectively), whereas BCVA in the PDT group was not. At 24 months, all eyes (100.0%) treated with anti-VEGF showed stable or improved BCVA, whereas 3 eyes (21.3%) showed visual deterioration after PDT. CONCLUSIONS: Anti-VEGF therapy was superior to PDT for idiopathic CNV, and superior efficacy was sustained until 24 months. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF OPHTHALMOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/therapeutic use | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Choroidal Neovascularization/drug therapy* | - |
dc.subject.MESH | Choroidal Neovascularization/physiopathology | - |
dc.subject.MESH | Coloring Agents | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorescein Angiography | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Indocyanine Green | - |
dc.subject.MESH | Intravitreal Injections | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Photochemotherapy* | - |
dc.subject.MESH | Photosensitizing Agents/therapeutic use | - |
dc.subject.MESH | Porphyrins/therapeutic use | - |
dc.subject.MESH | Ranibizumab | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tomography, Optical Coherence | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/antagonists & inhibitors* | - |
dc.subject.MESH | Visual Acuity/physiology | - |
dc.subject.MESH | Young Adult | - |
dc.title | Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | Hae Min Kang | - |
dc.contributor.googleauthor | Hyoung Jun Koh | - |
dc.identifier.doi | 10.1016/j.ajo.2012.10.010 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00095 | - |
dc.contributor.localId | A00152 | - |
dc.relation.journalcode | J00097 | - |
dc.identifier.eissn | 1879-1891 | - |
dc.identifier.pmid | 23219069 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0002939412007209 | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.keyword | Antibodies, Monoclonal, Humanized/therapeutic use | - |
dc.subject.keyword | Bevacizumab | - |
dc.subject.keyword | Choroidal Neovascularization/drug therapy* | - |
dc.subject.keyword | Choroidal Neovascularization/physiopathology | - |
dc.subject.keyword | Coloring Agents | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Fluorescein Angiography | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Indocyanine Green | - |
dc.subject.keyword | Intravitreal Injections | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Photochemotherapy* | - |
dc.subject.keyword | Photosensitizing Agents/therapeutic use | - |
dc.subject.keyword | Porphyrins/therapeutic use | - |
dc.subject.keyword | Ranibizumab | - |
dc.subject.keyword | Retrospective Studies | - |
dc.subject.keyword | Tomography, Optical Coherence | - |
dc.subject.keyword | Treatment Outcome | - |
dc.subject.keyword | Vascular Endothelial Growth Factor A/antagonists & inhibitors* | - |
dc.subject.keyword | Visual Acuity/physiology | - |
dc.subject.keyword | Young Adult | - |
dc.contributor.alternativeName | Kang, Hae Min | - |
dc.contributor.alternativeName | Koh, Hyoung Jun | - |
dc.contributor.affiliatedAuthor | Kang, Hae Min | - |
dc.contributor.affiliatedAuthor | Koh, Hyoung Jun | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 155 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 713 | - |
dc.citation.endPage | 719 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF OPHTHALMOLOGY, Vol.155(4) : 713-719, 2013 | - |
dc.identifier.rimsid | 29064 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.